Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (2733)	11/12/1997 6:42:00 PM
From: biopicker	Respond to of 6136

While we do have good news to report, the question is, "how much is it going to help?" This is a very tough market, and the company does well if it doesn't go down. Having said that, I again spoke with Agouron management today, and can tell you that the monthl figures were unexpedtedly strong. Both the overall market for protease inhibitors expanded, which of course if great news, and our competitive position improved as well. There is no question that our drug is the drug of choice, and will be #1 in its class before too long. Good Luck to All, and Keep the Faith! PS - One piece of advice - buy for cash and stay away from margin. It's in markets like this where investors can lose positions in excellent companies because of over-leveraging.